Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
Flash
01:21
Curve founder criticizes frequent DeFi vulnerabilities: single points of failure have become risks, calls for unified security standards
According to Odaily, Curve founder Michael Egorov posted on platform X that DeFi will continue to be the future of the global financial system, but a large number of recent security incidents—which could have been avoided and mostly stem from centralized single points of failure—are severely damaging the industry's development. He cited the Aave and rsETH incidents as examples, noting that although multiple parties claimed the “system was operating normally,” users were unable to withdraw funds. This exposes issues of infrastructure dependency and dispersed responsibility. Egorov stressed that the industry should reduce single point of failure risks beforehand, and when unavoidable, decentralize trust while sharing best practice configurations and security experiences. He called for the establishment of unified DeFi security standards and recommended that ecosystem organizations—including the Ethereum Foundation and Solana Foundation—take the lead in formulating and verifying principles and norms for security.
01:18
Eli Lilly acquires biotech company Kelonia for $7 billion to strengthen its cancer treatment portfolio
Glonghui, April 21 — Eli Lilly has agreed to acquire the clinical-stage biotechnology company Kelonia Therapeutics for up to $7 billion in order to strengthen its cancer treatment portfolio. The transaction includes a $3.25 billion cash upfront payment, with additional payments to be made based on the achievement of specific clinical, regulatory, and commercial milestones. The deal is subject to regulatory approval and is expected to be completed in the second half of this year. Through this acquisition, Eli Lilly will obtain Kelonia's main research candidate KLN-1010, which is used to treat multiple myeloma, a blood cancer that affects plasma cells in the bone marrow. The relevant product is currently undergoing phase 1 studies.
01:16
Institution: New Zealand's inflation outlook is worrying the Reserve Bank of New Zealand
Golden Ten Data reported on April 21 that Mark Smith, Senior Economist at New Zealand’s ASB Bank, stated that New Zealand’s overall annual inflation rate is expected to reach 4.5% in the second quarter and remain above 4% for the rest of 2026. He noted that the first quarter’s CPI data only reflected the initial impact of the US-Iran war, while the significant rise in oil and transport prices is expected to spread to broader overall price increases. Smith warned that the Reserve Bank of New Zealand’s 1%-3% inflation target may not be achieved until mid-2027, and there is a risk of a more significant overshoot.
News